Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Launch Date Nears, Is Ranbaxy Exploring Talks To Monetize Lipitor First-launch Opportunity With Generic Rivals?

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreement with Impax on launch of generic tamsulosin could be one model for atorvastatin strategy.

You may also be interested in...



Watson Talks Up Prochieve And Global Expansion At Analyst Meeting

Watson Pharmaceutical Inc.'s recent analyst meeting provided a substantial window on a company that is in the midst of a multi-year transformation, with insights into its growth strategy through 2013, but also with some potentially important qualifiers.

Watson Talks Up Prochieve And Global Expansion At Analyst Meeting

Watson Pharmaceutical Inc.'s recent analyst meeting provided a substantial window on a company that is in the midst of a multi-year transformation, with insights into its growth strategy through 2013, but also with some potentially important qualifiers.

Ranbaxy May Be Hit With Significant Disgorgement Penalty For GMP Violations

MUMBAI - Ranbaxy's long-running encounter with U.S. FDA over American regulatory allegations of significant deficiencies at two Ranbaxy manufacturing sites - Paonta Sahib and Dewas - may be headed for a settlement in coming months, with the Indian generics flag-bearer paying out several million dollars in penalties

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071473

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel